Q5160 HCPCS Level II code: Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg

Q5160 is the HCPCS code for “Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.

Official description

Q5160

Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg

Short description: Inj, jobevne, 10 mg

HCPCS · United States

Medicare details

The indicators CMS publishes with Q5160 in its October 2026 file. They describe Medicare’s handling, not another payer’s.

Medicare coverage: Carrier judgment
Medicare pricing: Drugs
Type of service: Medical care; Lump sum purchase of DME, prosthetics, orthotics
BETOS category: Chemotherapy
Added: Jan 1, 2026

Where Q5160 sits

1Q codesTemporary codes
2Active code Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg

Source and release

Data release: HCPCS Level II · October 2026
Effective date: Oct 1, 2026
Publisher: CMS

This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.

See Q5160 in the CMS source

Frequently asked questions

What does HCPCS code Q5160 mean?

Q5160 is the HCPCS code for “Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg” in CMS’s HCPCS Level II October 2026 release.

Does Medicare cover Q5160?

CMS lists Q5160’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.

Which HCPCS Level II release does this page use?

It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.

All Q codes